Botulinum toxin and other new approaches to migraine therapy

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 505-518

  Ashkenazi, Avi ^a   Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Angiotensin blockers; Antinociception; Headache; Prevention; Topiramate

Indexed keywords

ACETYLCHOLINE; AMINOGLYCOSIDE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROTOXIN; TOPIRAMATE;

ACETYLCHOLINE RELEASE; ADD ON THERAPY; ANALGESIC ACTIVITY; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ANTINOCICEPTION; AUTONOMIC NERVOUS SYSTEM; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CLUSTER HEADACHE; COGNITIVE DEFECT; COUGHING; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSTONIA; ESOPHAGUS ACHALASIA; HUMAN; LOW DRUG DOSE; MEDICAL ASSESSMENT; MIGRAINE; MONOTHERAPY; NAUSEA; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SCORING SYSTEM; SENSORY NERVE; SMOOTH MUSCLE RELAXATION; STRABISMUS; VISUAL ANALOG SCALE;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; RECEPTORS, ANGIOTENSIN;

EID: 1542329006     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104440     Document Type: Review

References (85)

1. Goadsby PJ, Lipton RB, Ferrari MD. 2002. Migraine - current understanding and treatment. N. Engl. J. Med. 346:257-70
2. World Health Organization. 2001. World Health Report. www.who.int/whr/index. htm.
3. Turton K, Chaddock JA, Acharya KR. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27:552-58
4. Brin MF. 1997. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 20:S146-S168
5. Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 129:221-28
6. Jankovic J, Brin MF. 1991. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 324:1186-94
7. Jankovic J, Brin ME. 1997. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 20:S129-S145
8. Silberstein SD. 2001. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin. Pharmacother. 2:1649-54
9. Critchfield J. 2002. Considering the immune response to botulinum toxin. Clin. J. Pain 18:S133-S141
10. Borodic G, Johnson E, Goodnough M, et al. 1996. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46:26-29
11. Dauer WT, Burke RE, Greene P, et al. 1998. Current concepts on the clinical features, aetioogy and management of idiopathic cervical dystonia. Brain 121:547-60
12. Zuber M, Sebald M, Bathien N, et al. 1995. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715-18
13. Greene P, Fahn S, Diamond B. 1994. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9:213-17
14. Jankovic J, Schwartz K. 1995. Response and immunoresistance to botulinum toxin injections. Neurology 45:1743-46
15. Dressler DW, Bigalke H, Benecke R. 2003. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Neurology 60:A465-A466 (Abstr.)
16. Sakamoto T, Asanuma K, Kaji R, et al. 2003. Development of a new low molecular weight botulinum type A neurotoxin preparation for treating muscle hyperactivity. Neurology 60:A466 (Abstr.)
17. Aoki KR. 2001. Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. 248:3-10
18. Naumann M, Jost WH, Toyka KV. 1999. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch. Neurol. 56:914-16
19. Heckmann M, Ceballos-Baumann AO, Plewig G, for the Hyperhidrosis Study Group. 2001. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N. Engl. J. Med. 344:488-93
20. Giladi N. 1997. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injection site. J. Neurol. Sci. 152:123-35
21. Filippi GM, Errico P, Santarelli R, et al. 1993. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 113:400-4
22. Resales RL, Arimura K, Takenaga S, et al. 1996. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488-96
23. Hallett M. 2000. How does botulinum toxin work? Ann. Neurol. 48:7-8
24. Wiegand H, Wellhoner HH. 1977. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch. Pharmacol. 298:235-38
25. Aoki R. 1998. The development of BOTOX - its history and pharmacology. Pain Digest 8:337-41
26. Janicki PK, Habermann E. 1983. Tetanus and botulinum toxins inhibit, and black widow spider venom stimulates the release of methionine-enkephalin-like material in vitro. J. Neurochem. 41:395-402
27. Byrnes ML, Thickbroom GW, Wilson SA, et al. 1998. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 121:977-88
28. Gilio F, Currà A, Lorenzano C, et al. 2000. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann. Neurol. 48:20-26
29. Gobel H, Heinze A, Kuhn KH, et al. 2001. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91:195-99
30. Borodic GE, Acquadro M, Johnson EA. 2001. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin. Investig. Drugs 10:1531-44
31. Arezzo JC. 2002. Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain 18:S125-S132
32. Cui M, Aoki KR. 2000. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414
33. Lew MF, Adornato BT, Duane D, et al. 1997. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701-7
34. Kramer HH, Angerer C, Erbguth F, et al. 2003. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J. Neurol. 250:188-93
35. Blersch W, Schulte-Mattler WJ, Przywara S, et al. 2002. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J. Neurol. Sci. 205:59-63
36. Ishikawa H, Mitsui Y, Yoshitomi T, et al. 2000. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 44:106-9
37. Welch MJ, Purkiss JR, Foster KA. 2000. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-58
38. Cui M, Li Z, You S, et al. 2003. Mechanisms of the antinociceptive effect of subcutaneous Botox®: inhibition of peripheral and central nociceptive processing. Arch. Pharmacol. 365:33 (Abstr.)
39. Munchau A, Bhatia KP. 2000. Uses of botulinum toxin injection in medicine today. BMJ 320:165
40. Scott AB, Magoon EH, McNeer KW, et al. 1990. Botulinum treatment of childhood strabismus. Ophthalmology 97:1434-38
41. Hughes AJ. 1994. Botulinum toxin in clinical practice. Drugs 48:888-93
42. Pasricha PJ, Ravich WJ, Kaloo AN. 1993. Botulinum toxin for achalasia. Lancet 341:244-45
43. Argoff CE 2002. A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain 6:S181
44. Difazio M, Jabbari B. 2002. A focused review of the use of botulinum toxins for low back pain. Clin. J. Pain 18:S155-S162
45. Freund BJ, Schwartz M. 2002. Use of botulinum toxin in chronic whiplash-associated disorder. Clin. J. Pain 18: S163-S168
46. Evers S, Rahmann A, Vollmer-Haase J, et al. 2002. Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia 22:699-710
47. Loder E, Biondi D. 2002. Use of botulinum toxins for chronic headaches: a focused review. Clin. J. Pain 18:S169-S176
48. Mathew NT, Kaup AO. 2002. The use of botulinum toxin type A in headache treatment Curr. Treatment Options Neurol. 4:365-73
49. Ashkenazi A, Silberstein SD. 2003. The evolving management of migraine. Curr. Opin. Neurol. 16(3):341-45
50. Binder WJ, Brin MF, Blitzer A, et al. 2000. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123:669-76
51. Silberstein SD, Mathew N, Saper J, et al. 2000. Botulinum toxin type A as a migraine preventive treatment. Headache 40:445-50
52. Brin MF, Swope DM, O'Brien C, et al. 2000. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 20: 421 (Abstr.)
53. Barrientos N, Chana P. 2002. Efficacy and safety of botulinum toxin type A (Botox®) in the prophylactic treatment of migraine. Headache 42:452 (Abstr.)
54. Behmand RA, Tucker T, Guyuron B, et al. 2002. Single-site Botox injection for the elimination of migraine trigger points. Headache 42:403 (Abstr.)
55. Relja MA, Klepac N. 2003. Botulinum toxin type-A reduces acute medication (triptans) use in migraine patients. Neurology 60:A321 (Abstr.)
56. Mauskop A, Basdeo R. 2000. Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalalgia 20:422 (Abstr.)
57. Smuts JA, Barnard PW. 2000. Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalalgia 20:332 (Abstr.)
58. Mathew NT, Kailasam J, Meadors L. 2002. "Disease modification" in chronic migraine with botulinum toxin type A: long-term experience. Headache 42:454-( Abstr.)
59. Robbins LD. 2001. Botulinum toxin A for refractory chronic daily headache. Cephalalgia 21:465 (Abstr.)
60. Ondo WG, Derman HS. 2002. Botulinum toxin A for chronic daily headache: a 60-patient, randomized, placebo-controlled, parallel design study. Headache 42:431 (Abstr.)
61. Scott AB. 1988. Antitoxin reduces botulinum side effects. Eye 2:29-32
62. Argov Z, Mastaglia FL. 1979. Disorders of neuromuscular transmission caused by drugs. N. Engl J. Med. 301:409-13
63. Lake AE, Saper JR. 2003. Botulinum toxin type B for migraine prophylaxis: a 4-month open-label prospective outcome study. Neurology 60:A322 (Abstr.)
64. Opida C. 2002. Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches. J. Pain 3:10 (Abstr.)
65. Gwynn MW, Baker T, English J. 2003. Double-blind, placebo-controlled study of botulinum toxin B for the treatment of chronic headache. Neurology 60:A322 (Abstr.)
66. Silberstein SD, Goadsby PJ. 2002. Migraine: preventive treatment. Cephalalgia 22:491-512
67. Langtry HD, Gillis JC, Davis R. 1997. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54:752-73
68. Galvez-Jimenez N, Hargreave M. 2000. Topiramate and essential tremor. Ann. Neurol. 47:837-38
69. Marcotte D. 1998. Use of topiramate, a new antiepileptic as a mood stabilizer. J. Affect. Disord. 50:245-51
70. Silberstein SD, Neto W, Jacobs D, et al. 2003. Efficacy and safety of topiramate in migraine prevention: a dose ranging placebo-controlled, double blind, multi-centered trial. Cephalalgia In press
71. Cutrer FM. 2001. Antiepileptic drugs: how they work in headache. Headache 41(Suppl. 1):S3-S10
72. Storer RJ, Goadsby PJ. 2003. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology 60:A238 (Abstr.)
73. Young WB, Hopkins MM, Shechter AL, et al. 2002. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 22:659-63
74. Mathew NT, Kailasam J, Meadors L. 2002. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42:796-803
75. Silberstein SD, Bhattacharaya S, Neto W, et al., for the MIGR-001 Study Group. 2003. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. Cephalagia In press
76. Brandes JL, Jacobs D, Neto W, et al. 2003. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled parallel study (MIGR-002). Neurology 60(Suppl. 1):A238 (Abstr.)
77. Storey JR, Calder CS, Hart DE, et al. 2001. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41:968-75
78. Von Seggern RL, Mannix LK, Adelman JU. 2002. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache 42:804-9
79. Bender WI. 1995. ACE inhibitors for prophylaxis of migraine headaches. Headache 35:470-71
80. Schrader H, Stovner LJ, Helde G, et al. 2001. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study. Br. J. Med. Psychol. 3222:19-22
81. Tronvik E, Stovner LJ, Helde G, et al. 2003. Prophylactic treatment of migraine with an angiotensin II receptor blocker a randomized controlled trial. JAMA 289:65-69
82. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31:2478-86
83. Mendelsohn FA, Jenkins TA, Berkovic SF. 1993. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613:221-29
84. Baltatu O, Afeche SC, Jose-dos Santos SH, et al. 2002. Locally synthesized angiotensin modulates pineal melatonin generation. J. Neurochem. 80:328-34
85. Reuter U, Chiarugi A, Bolay H, et al. 2002. Nuclear factor-κB as a molecular target for migraine therapy. Ann. Neurol. 51:507-16